Burden of Rett syndrome
6 evidence topics · 50 sources
Summary: definition and genetics
- Definition: Rett syndrome is a progressive neurodevelopmental disorder that affects mainly females. In classic Rett syndrome, psychomotor development appears normal for the first 6 to 18 months of life and is followed by regression of spoken language and purposeful hand use; this regression, together with hand stereotypies and impaired walking, forms the four principal diagnostic criteria. After regression, skills stabilize, and some individuals partly regain them.
- Genetics: pathogenic MECP2 variants are found in 95% to 97% of individuals with typical Rett syndrome and in 50% to 70% of those with atypical presentations, and 3% to 5% of individuals who meet strict clinical criteria have no identified MECP2 variant, so the diagnosis remains clinical. Variants in CDKL5 have been found in the early seizure variant.
- Inheritance: MECP2 disorders are X-linked, and more than 99% are simplex cases arising from a de novo variant or possibly from parental germline mosaicism. In 27 families with sporadic Rett syndrome, the de novo variant was of paternal origin in 26 of 27 cases (P<.001), which the authors propose as the most probable cause of the female predominance.
- Males: severe neonatal-onset encephalopathy is the most common phenotype in males with an MECP2 variant, and death often occurs before 2 years of age. Among 30 males with MECP2 variants in the Natural History Study databases, the phenotype ranged from severe neonatal encephalopathy to cognitive impairment.
Summary: incidence and prevalence
- Global estimates: a meta-analysis of 10 studies, all in females, with 9.57 million women and 673 cases, estimated a pooled prevalence of 7.1 per 100,000 females (95% CI 4.8 to 10.5), with study estimates ranging from 0.0 to 38.3 per 100,000 females; no included study had participants with Rett syndrome older than 35 years. Other sources give a worldwide prevalence of 1:10,000 to 1:23,000 female births and approximately 1 in 10,000 live female births. The Canadian trofinetide reimbursement review gives 1 in 10,000 females aged 12 years and younger and a worldwide prevalence of 1 in 20,000 to 1 in 40,000.
- Australia: among 349 females born from 1976 to 2006, the birth prevalence was 9.37 per 100,000 female births (95% CI 8.41 to 10.41). Point prevalence in June 2009 was 8.6 per 100,000 females aged 5 to 18 years (95% CI 7.4 to 10.1) and 5.8 per 100,000 females aged 19 to 32 years (95% CI 4.8 to 6.9).
- Cumulative incidence: another analysis reports a cumulative incidence of 1.09 per 10,000 females by 12 years of age.
- Europe: in France, the incidence of Rett syndrome with an MECP2 variant was 0.43 to 0.71 per 10,000 females, described as a minimum estimate, and the prevalence was 0.558 per 10,000 females aged 4 to 15 years. In Serbia, 102 girls were diagnosed from 1981 to 2012, an incidence of 0.586 per 10,000 female live births, and the prevalence in females younger than 19 years was 1:8,439.
- IQVIA claims: in the IQVIA Dx and LRx databases, annual prevalence from November 1, 2016 to October 31, 2019 was 0.30 to 0.32 per 10,000 enrollees overall and 0.45 to 0.52 per 10,000 among female enrollees. Annual incidence among female enrollees was 0.43 and 0.31 per 10,000 in 2018 and 2019.
- Canada: Ontario recorded 57 incident cases from September 2017 to August 2023 and 257 prevalent cases from April 2002 to August 2023. The trofinetide manufacturer estimated 600 to 900 cases in Canada, extrapolated from United States data.
- Company estimates: Acadia Pharmaceuticals estimates from 2024 claims that approximately 6,000 people in the United States are diagnosed, with a prevalent population of 6,000 to 9,000, and 9,000 to 12,000 in the European Union. Taysha Gene Therapies estimates 6,000 to 9,000 patients in the United States and an addressable population of 15,000 to 20,000 patients with typical Rett syndrome caused by a pathogenic or likely pathogenic MECP2 variant in the United States, the European Union, and the United Kingdom.
Summary: natural history and survival
- Regression: regression began between 12 and 30 months of age in more than 80% of individuals (36.2% at 12 to 18 months and 46.1% at 18 to 30 months), and another cohort reports a median of 18 months. The median age of skill loss was 3 years or younger for 46 of 51 developmental skills (90%). Regain of lost skills occurred mainly before 6 years of age, and after that age the gain of new skills or regain of lost skills was infrequent.
- Later life: in a cohort of 30 women, severity increased little over time, and some features, including epilepsy, agitation, sleep, and hand stereotypies, improved with age.
- Survival: in one cohort, 51 of 1189 participants died during 9 years of follow-up, survival exceeded 70% at 45 years for classic and atypical Rett syndrome, and at least 95% of the classic population was estimated to survive to age 20, 80% to age 35, and over 70% to age 50. In the Australian Rett Syndrome Database (n = 396), the conditional probability of survival was 77.6% at 20 years, 71.5% at 25 years, and 59.8% at 37 years. In a further analysis, 305 deaths (15.8%) had occurred as of January 1, 2006, and mortality was higher in typical than in atypical Rett syndrome (p<.0001). In a further cohort, median age at death was 13 years 4.8 months, and survival to 25 years was 21% against 71% in the Australian cohort (p<0.001).
- Causes of death: among 57 deceased females with a recorded cause, lower respiratory tract infection accounted for 36.8% (21/57), aspiration or asphyxiation for 31.6% (18/57), respiratory failure for 14.0% (8/57), and seizure-related illness for 5.3% (3/57). Cardiorespiratory dysfunction may account for 26% to 47% of sudden, unexpected deaths.
- Risk factors: in classic Rett syndrome, ambulation status, frequent seizures, frequent hospitalizations and illness, microcephaly, and low weight were independently associated with mortality, and 54% (19/35) of those who died weighed less than the 25th percentile on Rett-specific charts against 22% of survivors (p < .001).
Summary: symptom domains and long-term morbidity
- Range across studies: a systematic review of 148 studies from 24 countries, with participants aged 7 months to 37 years, reports prevalence ranges of 15.0% to 91.0% for epilepsy, 8.9% to 100% for scoliosis, 16.4% to 82.8% for constipation, 15.8% to 100.0% for gastroesophageal reflux, 68.0% to 100.0% for intellectual disability, 18.2% to 95.5% for dystonia, 23.5% to 76.7% for dysphagia and chewing problems, and 39.2% to 92.9% for drooling.
- Motor and communication: nearly 100% of individuals had abnormal hand function, more than 70% had delayed walking, and nearly 34% never acquired walking. Hand stereotypies were reported in all 922 participants with classic Rett syndrome. Nearly all participants had delayed language development and 90% had abnormal nonverbal communication; 88.6% lost previously gained words with meaning.
- Seizures and autonomic function: the point prevalence of active seizures was 30% to 44% and the estimated cumulative lifetime prevalence of epilepsy approached 90%. Breathing dysfunction affected nearly 100% of those with classic or atypical severe Rett syndrome over the lifespan and 60% to 70% of those with atypical mild Rett syndrome. Of 613 participants with electrocardiogram data, 18% had a borderline and 10% an abnormal QTc interval.
- Gastrointestinal, sleep, and behavior: gastrointestinal and orthopaedic comorbidities are each reported in over 80% of individuals in one publication, and gastrointestinal manifestations that led to a healthcare encounter were recorded in 43.0% of 5940 patients. Sleep problems were identified in over 80% of cases, and 77.5% of participants had at least occasional anxious or nervous behavior. Mean head circumference fell below the normative population at 1 month, weight at 6 months, and length at 17 months.
- Orthopaedic and bone: a meta-analysis estimates that approximately two in three girls develop scoliosis, one in two foot deformities, and one in three hip displacement. Among 913 females with classic Rett syndrome, 251 (27%) had severe scoliosis and 168 (18%) had surgical correction, at a median age of 12 years. Fracture incidence in an Australian population was 43.3 per 1000 person years, nearly four times that of the general population.
- Adulthood: in a cohort with a median age of 25 years (range 18 to 54), 71% lived in the parental home, 18% walked independently and 43% with assistance, 86% had scoliosis (40% of them corrected surgically), 64% took antiepileptic medication, 83% had constipation, and 63% had sleep disturbance. Among 24 individuals aged 30 to 66 years followed for 6 to 12 years, gross motor scores declined. Of 26 women who walked after childhood regression, 2 (8%) lost walking in their 20s, and 9 (37.5%) of those still walking in their 40s lost it in their 40s or 50s.
- Respiratory complications: of 1,994 individuals in one analysis, 7.27% had aspiration, 9.48% lower respiratory tract infection, and 10.08% respiratory failure after the index date.
Summary: humanistic burden
- Quality of life of the affected individual: among more than 200 participants aged 5 to 18 years with classic Rett syndrome, every CHQ-PF50 domain score other than Behavior and Family Cohesion was significantly lower than the standard score for US girls. The 23 parents in another study rated their children's quality of life as reduced.
- Caregiver health: in one cohort, caregivers had a mean physical component score of 52.8 (9.7) and a mental component score reported as 44.5 (12.1) and, in the comparison with the general population, 44.6 (12.1); females aged 35 to 44 years in the US general population score 51.6 (8.6) and 47.8 (10.4). Among 37 UK caregivers in a multi-method study conducted from June to August 2025, the mean EQ-5D-5L score was 0.62 (SD=0.25), 49% reported moderate to severe anxiety or depression, 38% reported moderate to severe pain or discomfort, and the mean CarerQoL-7D utility was 60.76 (SD=18.11). In another study, 60% of parents reported stress in the clinical range on at least one Parenting Stress Index subscale.
- Symptoms with the greatest impact: in an international survey of 756 caregivers, core impairments were present in 70% to 98% of affected individuals, and problem frequency ranged from about 35% for hyperventilation to 99% for impaired self-care. In a survey of 323 caregivers in the USA, the UK, Canada, and Israel funded by Taysha Gene Therapies, loss of speech (81%, n = 261), loss of purposeful hand use (80%, n = 259), and loss of independent walking (61%, n = 198) were most often rated as having a severe impact on quality of life, and 76% (n = 245) reported at least 1 new or newly challenging symptom in the previous 2 years.
- Daily activities: in diaries from 60 caregivers in eight countries, symptoms affected 59% of activities for children, 61% for adolescents, and 38% for adults, and caregivers of adults spent an average of 41 hours per week on emotional support and 20 hours on feeding.
Summary: economic burden
- IQVIA claims: among 5,940 female patients (3,078 pediatric and 2,862 adult) in the IQVIA Dx and LRx databases from November 1, 2016 to October 31, 2019, with a mean observation period of 2.04 years, mean all-cause healthcare costs were $40,326 per patient per year in 2021 US dollars, $45,718 for pediatric and $34,548 for adult patients. Costs related to Rett syndrome made up 45% of all-cause costs. All-cause resource use was 44.43 visits per patient per year, led by home or hospice care (16.31 visits). The authors note that pre-adjudicated medical claims may overestimate costs. Managing gastrointestinal manifestations cost a mean of $4473 per patient per year.
- Other settings: in the Australian Rett Syndrome Database, mean healthcare costs were AUD 21,158 per patient per year (USD 25,691 as of December 2022), ranging from AUD 238 to AUD 85,776. Among 246 cases in Ontario, 76.8% had an emergency department visit and 54.5% an inpatient hospitalization. In another cohort, 44.6% of individuals had a hospital or emergency room visit over a median of 4 years, and 13.7% had a gastrostomy tube placed.
- Surgery: in the Kids' Inpatient Database, a Rett syndrome diagnosis independently predicted higher odds of complications (odds ratio 1.98) and longer stay (odds ratio 1.18) for posterior spinal fusion admissions.
- Families: among 37 UK caregivers, caregiving averaged 98.9 hours per week, 14% worked full time, and 60% had stopped working.
- Diagnostic testing: Prices for MECP2 sequencing (CPT 81302) were $685 in one price list and $900 in another. The Canadian reimbursement review estimates approximately $1,307.45 per sample for MECP2 testing.
- Evidence base: a literature review found cost or resource use outcomes in 11 publications and no pharmacoeconomic models or comprehensive estimates of total economic burden.